Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-20-073422
Filing Date
2020-06-15
Accepted
2020-06-15 16:40:50
Documents
2
Group Members
NOVARTIS

Document Format Files

Seq Description Document Type Size
1 SC 13G tm2022574d1_sc13g.htm SC 13G 48060
2 EXHIBIT 99.1 tm2022574d1_ex99-1.htm EX-99.1 5182
  Complete submission text file 0001104659-20-073422.txt   54757
Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Filed by) CIK: 0001673852 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Subject) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91525 | Film No.: 20963891
SIC: 2834 Pharmaceutical Preparations